
Roongroj Bhidayasiri, Frcp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5698515/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence-based guideline: Treatment of tardive syndromes. Neurology, 2013, 81, 463-469.	1.1	189
2	A hypothetical scheme for the brainstem control of vertical gaze. Neurology, 2000, 54, 1985-1993.	1.1	150
3	Expanding use of botulinum toxin. Journal of the Neurological Sciences, 2005, 235, 1-9.	0.6	138
4	Differential diagnosis of common tremor syndromes. Postgraduate Medical Journal, 2005, 81, 756-762.	1.8	132
5	Systematic review of hardware-related complications of Deep Brain Stimulation: Do new indications pose an increased risk?. Brain Stimulation, 2017, 10, 967-976.	1.6	118
6	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
7	Late-Onset Friedreich Ataxia. Archives of Neurology, 2005, 62, 1865.	4.5	111
8	Management of non-motor symptoms in advanced Parkinson disease. Journal of the Neurological Sciences, 2008, 266, 216-228.	0.6	97
9	Chorea and related disorders. Postgraduate Medical Journal, 2004, 80, 527-534.	1.8	88
10	Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences, 2018, 389, 67-75.	0.6	88
11	Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotoxicity Research, 2016, 29, 105-117.	2.7	79
12	Spectrum of tardive syndromes: clinical recognition and management. Postgraduate Medical Journal, 2011, 87, 132-141.	1.8	77
13	COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care. Journal of Movement Disorders, 2020, 13, 105-114.	1.3	70
14	Clinical Assessments in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 129-182.	2.0	63
15	Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. Journal of Neural Transmission, 2014, 121, 59-68.	2.8	57
16	A newly identified locus for benign adult familial myoclonic epilepsy on chromosome 3q26.32-3q28. European Journal of Human Genetics, 2013, 21, 225-228.	2.8	55
17	Midbrain Ataxia: An Introduction to the Mesencephalic Locomotor Region and the Pedunculopontine Nucleus. American Journal of Roentgenology, 2005, 184, 953-956.	2.2	51
18	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51

#	Article	IF	CITATIONS
19	Parkinson's Disease and <scp>Post–COVID</scp> â€19 Syndrome: The Parkinson's <scp>Longâ€COVID</scp> Spectrum. Movement Disorders, 2021, 36, 1287-1289.	3.9	51
20	Bilateral neurostimulation systems used for deep brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the brain. Magnetic Resonance Imaging, 2005, 23, 549-555.	1.8	49
21	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Movement Disorders, 2019, 34, 791-798.	3.9	49
22	Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences, 2008, 266, 204-215.	0.6	48
23	Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 89-103.	0.7	48
24	The impact of the nocturnal disabilities of Parkinson's disease on caregivers' burden: implications for interventions. Journal of Neural Transmission, 2014, 121, 15-24.	2.8	47
25	How well do Parkinson's disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. Parkinsonism and Related Disorders, 2016, 23, 10-16.	2.2	46
26	Saccadic and Vestibular Abnormalities in Multiple Sclerosis. Annals of the New York Academy of Sciences, 2002, 956, 438-440.	3.8	43
27	Dystonia. Neurologist, 2006, 12, 74-85.	0.7	43
28	Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. Journal of Neurology, 2011, 258, 2069-2074.	3.6	43
29	Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study. Journal of the Neurological Sciences, 2016, 367, 162-170.	0.6	43
30	Six Action Steps to Address Global Disparities in Parkinson Disease. JAMA Neurology, 2022, 79, 929.	9.0	39
31	Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience. International Journal of Neuroscience, 2012, 122, 145-153.	1.6	37
32	Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 10-18.	2.2	37
33	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
34	Treatment of dystonia. Expert Review of Neurotherapeutics, 2006, 6, 863-886.	2.8	33
35	Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. Movement Disorders, 2010, 25, 1895-1901.	3.9	33
36	HIV-related opsoclonus–myoclonus–ataxia syndrome: Report on two cases. Clinical Neurology and Neurosurgery, 2010, 112, 572-574.	1.4	33

#	Article	IF	CITATIONS
37	Transplacental transfer of NMDA receptor antibodies in an infant with cortical dysplasia. Neurology, 2014, 82, 1662-1663.	1.1	33
38	A National Registry to Determine the Distribution and Prevalence of Parkinson's Disease in Thailand: Implications of Urbanization and Pesticides as Risk Factors for Parkinson's Disease. Neuroepidemiology, 2011, 37, 222-230.	2.3	32
39	Movement disorders in patients with diabetes mellitus. Journal of the Neurological Sciences, 2012, 314, 5-11.	0.6	32
40	Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 61-67.	2.2	32
41	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	3.6	32
42	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S49-S55.	2.2	31
43	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	2.8	31
44	Effects of Transcranial Direct Current Stimulation Plus Physical Therapy on Gait in Patients With Parkinson Disease. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 7-15.	1.4	31
45	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. Movement Disorders, 2021, 36, 76-82.	3.9	31
46	The spectrum of preclinical gait disorders in early Parkinson's disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking. Journal of Neural Transmission, 2013, 120, 1665-1672.	2.8	29
47	Temporal fluctuations of tremor signals from inertial sensor: a preliminary study in differentiating Parkinson's disease from essential tremor. BioMedical Engineering OnLine, 2015, 14, 101.	2.7	29
48	Sensor-based evaluation and treatment of nocturnal hypokinesia in Parkinson's disease: An evidence-based review. Parkinsonism and Related Disorders, 2016, 22, S127-S133.	2.2	29
49	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. Neuroepidemiology, 2017, 49, 1-17.	2.3	29
50	Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism and Related Disorders, 2017, 44, 124-128.	2.2	29
51	Exploring the effect of electrical muscle stimulation as a novel treatment of intractable tremor in Parkinson's disease. Journal of the Neurological Sciences, 2015, 358, 146-152.	0.6	28
52	Practical management of adverse events related to apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S42-S48.	2.2	28
53	Tremor's glove-an innovative electrical muscle stimulation therapy for intractable tremor in Parkinson's disease: A randomized sham-controlled trial. Journal of the Neurological Sciences, 2017, 381, 331-340.	0.6	28
54	Evidence for effectiveness of botulinum toxin for hyperhidrosis. Journal of Neural Transmission, 2008, 115, 641-645.	2.8	27

#	Article	IF	CITATIONS
55	Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors. Parkinsonism and Related Disorders, 2016, 33, S36-S41.	2.2	27
56	Support vector machine classification of Parkinson's disease and essential tremor subjects based on temporal fluctuation. , 2016, 2016, 6389-6392.		27
57	Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism and Related Disorders, 2015, 21, 111-115.	2.2	26
58	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. Parkinsonism and Related Disorders, 2021, 89, 186-194.	2.2	26
59	Multiple System Atrophy. Neurologist, 2008, 14, 224-237.	0.7	25
60	What is the evidence to support home environmental adaptation in Parkinson's disease? A call for multidisciplinary interventions. Parkinsonism and Related Disorders, 2015, 21, 1127-1132.	2.2	25
61	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. Parkinsonism and Related Disorders, 2020, 72, 82-87.	2.2	25
62	Capturing nighttime symptoms in Parkinson disease: Technical development and experimental verification of inertial sensors for nocturnal hypokinesia. Journal of Rehabilitation Research and Development, 2016, 53, 487-498.	1.6	25
63	Midbrain Ataxia: Possible Role of the Pedunculopontine Nucleus in Human Locomotion. Cerebrovascular Diseases, 2003, 16, 95-96.	1.7	24
64	Identifying gaps in knowledge about Parkinson disease among medical professionals in Thailand. Neurology, 2014, 82, 2238-2240.	1.1	24
65	Knowledge, attitudes and perceptions of Parkinson's disease: A cross-sectional survey of Asian patients. Journal of the Neurological Sciences, 2017, 374, 69-74.	0.6	23
66	Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: the case for a higher priority and stronger evidence. Parkinsonism and Related Disorders, 2012, 18, S110-S113.	2.2	22
67	Asian perspectives on the recognition and management of levodopa â€~wearing-off' in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1285-1297.	2.8	22
68	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 59, 82-92.	2.2	22
69	Post-hypoxic animal model of myoclonus. Parkinsonism and Related Disorders, 2007, 13, 377-381.	2.2	21
70	Treatment of complex cervical dystonia with botulinum toxin: Involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism and Related Disorders, 2011, 17, S20-S24.	2.2	21
71	Prevalence of neuroleptic-induced restless legs syndrome in patients taking neuroleptic drugs. Journal of the Neurological Sciences, 2012, 314, 158-160.	0.6	21
72	Visual deprivation elicits subclinical postural inflexibilities in early Parkinson's disease. Journal of the Neurological Sciences, 2015, 349, 214-219.	0.6	21

#	Article	IF	CITATIONS
73	Time for a strategy in night-time dopaminergic therapy? An objective sensor-based analysis of nocturnal hypokinesia and sleeping positions in Parkinson's disease. Journal of the Neurological Sciences, 2017, 373, 244-248.	0.6	21
74	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Scientific Reports, 2021, 11, 9611.	3.3	21
75	A census of movement disorders at a Thai university hospital. Journal of the Neurological Sciences, 2011, 301, 31-34.	0.6	19
76	Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study. BMC Neurology, 2015, 15, 166.	1.8	19
77	Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism and Related Disorders, 2016, 33, S2-S8.	2.2	19
78	What daily activities increase the risk of falling in Parkinson patients? An analysis of the utility of the ABC-16 scale. Journal of the Neurological Sciences, 2016, 364, 183-187.	0.6	19
79	RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. Journal of Clinical Movement Disorders, 2017, 4, 9.	2.2	19
80	Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Medical Hypotheses, 2005, 64, 941-945.	1.5	18
81	Evidence for the effectiveness of botulinum toxin for sialorrhoea. Journal of Neural Transmission, 2008, 115, 631-635.	2.8	18
82	Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care. Parkinsonism and Related Disorders, 2020, 80, 35-40.	2.2	18
83	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. Movement Disorders, 2022, 37, 182-189.	3.9	18
84	How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Translational Neurodegeneration, 2019, 8, 20.	8.0	17
85	Ocular oscillations induced by shifts of the direction and depth of visual fixation. Annals of Neurology, 2001, 49, 24-28.	5.3	16
86	Three brothers with a very-late-onset writer's cramp. Movement Disorders, 2005, 20, 1375-1377.	3.9	16
87	A low-cost intervention for improving gait in Parknson's disease patients: A cane providing visual cues. European Geriatric Medicine, 2012, 3, 126-130.	2.8	16
88	Different diagnostic criteria for Parkinson disease: what are the pitfalls?. Journal of Neural Transmission, 2013, 120, 619-625.	2.8	16
89	Low-Cost, 3-Dimension, Office-Based Inertial Sensors for Automated Tremor Assessment: Technical Development and Experimental Verification. Journal of Parkinson's Disease, 2014, 4, 273-282.	2.8	16
90	The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. Expert Review of Neurotherapeutics, 2021, 21, 615-623.	2.8	15

#	Article	IF	CITATIONS
91	Task Force Consensus on Nosology and Cutâ€Off Values for Axial Postural Abnormalities in Parkinsonism. Movement Disorders Clinical Practice, 2022, 9, 594-603.	1.5	15
92	Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Functional Neurology, 2012, 27, 225-30.	1.3	14
93	Startle syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 421-430.	1.8	13
94	Can therapeutic Thai massage improve upper limb muscle strength in Parkinson's disease? An objective randomized-controlled trial. Journal of Traditional and Complementary Medicine, 2018, 8, 261-266.	2.7	13
95	Parkinson's disease severity clustering based on tapping activity on mobile device. Scientific Reports, 2022, 12, 3142.	3.3	13
96	Prevalence and diagnostic challenge of dystonia in Thailand: A service-based study in a tertiary university referral centre. Parkinsonism and Related Disorders, 2011, 17, S15-S19.	2.2	12
97	The sleeping brain in Parkinson's disease: A focus on REM sleep behaviour disorder and related parasomnias for practicing neurologists. Journal of the Neurological Sciences, 2017, 374, 32-37.	0.6	12
98	Symptomatic orthostatic hypotension in Parkinson's disease patients: Prevalence, associated factors and its impact on balance confidence. Journal of the Neurological Sciences, 2018, 385, 168-174.	0.6	12
99	Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clinical Neuropharmacology, 2019, 42, 172-178.	0.7	12
100	Expanding spectrum of abnormal movements in MELAS syndrome (mitochondrial encephalomyopathy,) Tj ETQqC	0 0 rgBT	/Overlock 10
101	Boxing and Parkinson disease: A link or a myth? An 18F-FDOPA PET/CT study in retired Thai traditional boxers. Parkinsonism and Related Disorders, 2012, 18, 694-696.	2.2	11
102	Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism and Related Disorders, 2019, 66, 94-99.	2.2	11
103	Monoamine Levels and Parkinson's Disease Progression: Evidence From a High-Performance Liquid Chromatography Study. Frontiers in Neuroscience, 2021, 15, 605887.	2.8	11
104	Reduced Serum Caeruloplasmin Levels in Non-Wilsonian Movement Disorders. European Neurology, 2011, 66, 123-127.	1.4	10
105	The Arizona Sexual Experiences Scale: A Validity and Reliability Assessment of the Thai Translation (ASEX-Thai) in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 205-210.	2.8	10
106	Evaluation of nocturnal hypokinesia in Parkinson's disease using a novel patient/proxy questionnaire and correlations with objective monitoring. Parkinsonism and Related Disorders, 2019, 61, 219-223.	2.2	10
107	<p>If Your Patients Were Too Embarrassed to Go Out in Public, What Would You Do? – Public Education to Break the Stigma on Parkinson's Disease Using Integrated Media</p> . Patient Related Outcome Measures, 2020, Volume 11, 143-148.	1.2	10
108	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology. Journal of the Neurological Sciences, 2022, 435, 120197.	0.6	10

#	Article	IF	CITATIONS
109	Complex movement disorders in a sporadic Boucherâ€Neuhäser Syndrome: Phenotypic manifestations beyond the triad. Movement Disorders, 2009, 24, 2304-2306.	3.9	9
110	Physicians' role in the determination of fitness to drive in patients with Parkinson's disease: systematic review of the assessment tools and a call for national guidelines. Journal of Clinical Movement Disorders, 2016, 3, 14.	2.2	9
111	Favorable longitudinal outcome in a patient with Parry-Romberg syndrome. Acta Neurologica Scandinavica, 2005, 112, 192-193.	2.1	8
112	Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation. Movement Disorders, 2009, 24, 1848-1849.	3.9	8
113	Nocturnal Manifestations of Atypical Parkinsonian Disorders. Journal of Parkinson's Disease, 2014, 4, 223-236.	2.8	8
114	Impaired bed mobility: quantitative torque analysis with axial inertial sensors. Neurodegenerative Disease Management, 2017, 7, 235-243.	2.2	8
115	Subthalamic deep brain stimulation aggravates speech problems in Parkinson's disease: Objective and subjective analysis of the influence of stimulation frequency and electrode contact location. Parkinsonism and Related Disorders, 2019, 66, 110-116.	2.2	8
116	Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. Parkinsonism and Related Disorders, 2019, 59, 74-81.	2.2	8
117	Using Machine Learning for Predicting the Best Outcomes With Electrical Muscle Stimulation for Tremors in Parkinson's Disease. Frontiers in Aging Neuroscience, 2021, 13, 727654.	3.4	8
118	Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management. PLoS ONE, 2020, 15, e0243051.	2.5	8
119	Correction of mesalazine-induced neutropenia with high dose G-CSF. American Journal of Gastroenterology, 2000, 95, 3321-3322.	0.4	7
120	Dystonia (DYT) genetic loci. European Journal of Paediatric Neurology, 2005, 9, 367-370.	1.6	7
121	Tremor assessment using spiral analysis in time-frequency domain. , 2013, , .		7
122	Association between Sleep Disturbances and Daytime Somnolence in Parkinson's Disease. European Neurology, 2018, 80, 268-276.	1.4	7
123	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	2.8	7
124	Ixcellence Networkïį1⁄2: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. Functional Neurology, 2017, 32, 103.	1.3	7
125	Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?. PLoS ONE, 2021, 16, e0261302.	2.5	7
126	Segmental Unilateral Lentiginosis in Generalized Neurofibromatosis Type 1. Archives of Neurology, 2002, 59, 1331.	4.5	6

#	Article	IF	CITATIONS
127	"Dystonic―body perception in childhood dystonia. Clinical Neurology and Neurosurgery, 2007, 109, 446-447.	1.4	6
128	The first case report of neuroacanthocytosis in Thailand: Utilization of a peripheral blood smear technique for detecting acanthocytes. Clinical Neurology and Neurosurgery, 2010, 112, 541-543.	1.4	6
129	Positional Vomiting as the Initial Manifestation of Bruns Syndrome due to Cysticercosis in the Fourth Ventricle: A Symptom Reminiscent of an Old Disease. European Neurology, 2012, 67, 184-185.	1.4	6
130	Orofacial dystonia and asssociated bulbar symptoms in multiple system atrophy: A blinded video analysis. Journal of the Neurological Sciences, 2020, 417, 116992.	0.6	6
131	Objective vowel sound characteristics and their relationship with motor dysfunction in Asian Parkinson's disease patients. Journal of the Neurological Sciences, 2021, 426, 117487.	0.6	6
132	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinson's disease: A Prospective Analysis of the Thai Apomorphine Registry. Parkinsonism and Related Disorders, 2021, 91, 146-151.	2.2	6
133	Beyond the Classic Segawa Disease, GCH1-Associated Neurodegenerative Parkinsonism: Practical Considerations for Physicians. Journal of Movement Disorders, 2017, 10, 102-104.	1.3	6
134	How useful is (1231) beta-CIT SPECT in the diagnosis of Parkinson's disease?. Reviews in Neurological Diseases, 2006, 3, 19-22.	0.3	6
135	Myoclonus and parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 549-560.	1.8	5
136	Lingual myoclonus secondary to bilateral cortical strokes in a probable case of antiphospholipid syndrome. Movement Disorders, 2010, 25, 2000-2002.	3.9	5
137	Nocturnal manifestations of atypical and vascular parkinsonism: How do they differ from Parkinson's disease?. Journal of Neural Transmission, 2014, 121, 69-77.	2.8	5
138	Objective Measurement and Monitoring of Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 347-387.	2.0	5
139	Exploring Bedroom Usability and Accessibility in Parkinson's Disease (PD): The Utility of a PD Home Safety Questionnaire and Implications for Adaptations. Frontiers in Neurology, 2018, 9, 360.	2.4	5
140	Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses. Clinical Therapeutics, 2019, 41, 2321-2330.e4.	2.5	5
141	Mastering nocturnal jigsaws in Parkinson's disease: a dusk-to-dawn review of night-time symptoms. Journal of Neural Transmission, 2020, 127, 763-777.	2.8	5
142	Impaired ability to turn in bed in parkinson's disease as a potential rare cause of positional asphyxia: a sensor-based analysis. Clinical Neurology and Neurosurgery, 2020, 192, 105713.	1.4	5
143	Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey. Frontiers in Neurology, 2020, 11, 570671.	2.4	4
144	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism and Related Disorders, 2020, 77, 141-145.	2.2	4

#	Article	IF	CITATIONS
145	Addressing knowledge gaps in Parkinson's disease: a report on the Movement Disorder Society's Centre-to-Centre initiative to improve Parkinson's disease services in Lao People's Democratic Republic. BMC Medical Education, 2020, 20, 239.	2.4	4
146	Challenges of Parkinson's Disease Care in Southeast Asia. , 2021, , 1-21.		4
147	Will Artificial Intelligence Outperform the Clinical Neurologist in the Near Future? Yes. Movement Disorders Clinical Practice, 2021, 8, 525-528.	1.5	4
148	Umami and Other Taste Perceptions in Patients With Parkinson's Disease. Journal of Movement Disorders, 2022, 15, 115-123.	1.3	4
149	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. Journal of Movement Disorders, 2022, 15, 151-155.	1.3	4
150	More than hemifacial spasm? A case of unilateral facial spasms with systematic review of red flags. Journal of the Neurological Sciences, 2019, 407, 116532.	0.6	3
151	Using machine learning-based analytics of daily activities to identify modifiable risk factors for falling in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 82, 77-83.	2.2	3
152	Editorial: Inclusion, equity, diversity and social justice in movement disorders research. Parkinsonism and Related Disorders, 2021, 85, 114-116.	2.2	3
153	Impact of <scp>COVIDâ€19</scp> on Patient Care, Training, and Research in Movement Disorders in <scp>MDSâ€AOS</scp> Region. Movement Disorders, 2021, 36, 2457-2458.	3.9	3
154	A South East Asian perspective of neuropsychiatric startle syndromes of latah. Parkinsonism and Related Disorders, 2022, 95, 138-142.	2.2	3
155	Wound botulism. Postgraduate Medical Journal, 2004, 80, 240-240.	1.8	2
156	Postmortem analysis of pallidotomy in Parkinson?s disease. Journal of Neurology, 2005, 252, 100-102.	3.6	2
157	Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy. Clinical Neurology and Neurosurgery, 2014, 116, 1-3.	1.4	2
158	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	1.5	2
159	Tourette's syndrome: old syndrome, new insights and new treatment. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88 Suppl 4, S339-47.	0.1	2
160	Atypical dementia: when it is not Alzheimer's disease. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2007, 90, 2222-32.	0.1	2
161	Subdural Hematoma and Retinal Hemorrhages in an Infant: Accidental or Nonaccidental Injury?. Pediatric Neurosurgery, 2004, 40, 147-148.	0.7	1
162	Juvenile parkinsonism. European Journal of Paediatric Neurology, 2009, 13, 290-292.	1.6	1

#	Article	IF	CITATIONS
163	The first case report of neuroacanthocytosis in Thailand: Utilization of a proper technique searching for acanthocytes. Clinical Neurology and Neurosurgery, 2012, 114, 425-426.	1.4	1
164	Recurrent pancreatitis as a rare complication of duodenal levodopa infusion treatment. Movement Disorders, 2013, 28, 1308-1310.	3.9	1
165	Nocturnal manifestations of Parkinson's disease and atypical Parkinsonism. Journal of Neural Transmission, 2014, 121, 1-2.	2.8	1
166	Oneiric stupor in a 45-year-old nurse with rapidly progressive dementia: What is the diagnosis?. Clinical Neurology and Neurosurgery, 2015, 137, 102-104.	1.4	1
167	Editorial and introduction: Behavioral aspects of Parkinson's disease. Journal of the Neurological Sciences, 2017, 374, 1-2.	0.6	1
168	Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns. Parkinsonism and Related Disorders, 2021, 87, 39-40.	2.2	1
169	Stroke: An Overview. , 0, , 1-1.		1
170	Assistive technologies in Parkinson's disease. , 2020, , 713-729.		1
171	Axial Sensory Tricks in Chorea-Acanthocytosis: Insights into Phenomenology. Tremor and Other Hyperkinetic Movements, 2017, 7, 475.	2.0	1
172	We Move or Are We Moved? Unpicking the Origins of Voluntary Movements to Better Understand Semivoluntary Movements. Frontiers in Neurology, 2022, 13, 834217.	2.4	1
173	Cerebellar arteriovenous malformation presenting with bilateral proptosis mimicking caroticocavernous fistula. British Journal of Hospital Medicine, 2004, 65, 690-691.	0.2	0
174	Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences, 2008, 273, 156-157.	0.6	0
175	Introduction. Parkinsonism and Related Disorders, 2011, 17, S1-S2.	2.2	0
176	10 Commonly Asked Questions About Parkinson Disease. Neurologist, 2011, 17, 57-62.	0.7	0
177	Parkinson's Disease: Levodopa-Induced Dyskinesia. Current Clinical Neurology, 2012, , 10-11.	0.2	0
178	Opsoclonus-Myoclonus-Ataxia Syndrome. Current Clinical Neurology, 2012, , 196-197.	0.2	0
179	Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2013, 81, 1967-1967.	1.1	0

Botulinum neurotoxin in oromandibular dystonia. , 0, , 64-70.

#	Article	IF	CITATIONS
181	Introducing the new "Movement Disorders Rounds― Parkinsonism and Related Disorders, 2018, 55, 1.	2.2	0
182	Objective Monitoring of Driving Behavior in Parkinson's Disease: The Utility of the Chula Parkinson Car®. European Neurology, 2019, 81, 128-138.	1.4	0
183	Prescription of Anticholinergics in Tardive Syndromes: A "Dual Center―Survey among Psychiatrists. Parkinson's Disease, 2020, 2020, 1-4.	1.1	0
184	Urinary dysfunction in Parkinson's disease. International Review of Movement Disorders, 2021, , 209-249.	0.1	0
185	Peak-Dose Ballism Associated with Declining Implantable Pulse Generator Battery Life in Deep Brain Stimulation for Parkinson's Disease. Journal of Movement Disorders, 2021, 14, 166-169.	1.3	0
186	Subdural Empyema. , 0, , 245-247.		0
187	Appendix: Treatment Algorithm for Parkinson's Disease. , 0, , 681-682.		0
188	Disorders of Amino Acid, Organic Acid, and Ammonia Metabolism. , 0, , 609-616.		0
189	Introduction to Protozoans of the Central Nervous System. , 0, , 278-278.		0
190	Movement Disorders: An Overview. , 0, , 144-145.		0
191	Scapuloperoneal Syndrome. , 0, , 225-226.		0
192	Floppy Infant Syndrome. , 0, , 596-599.		0
193	Sleep Abnormalities in Neurological Disorders. , 0, , 577-578.		0
194	HIV and the Acquired Immunodeficiency Syndrome: An Overview of Neurological Complications. , 0, , 340-341.		0
195	Rickettsial and Parasitic Infections. , 0, , 293-293.		0
196	Facial and Neck Pain. , 0, , 675-678.		0
197	Mycobacterium Avium. , 0, , 261-261.		0
198	Genetics in Neurology. , 0, , 480-484.		0

#	Article	IF	CITATIONS
199	Tardive Dystonia. Current Clinical Neurology, 2012, , 126-127.	0.2	Ο
200	Examination of a Patient with Non-DYT1 Generalized Dystonia. Current Clinical Neurology, 2012, , 78-79.	0.2	0
201	Chorea-Acanthocytosis with Feeding Dystonia. Current Clinical Neurology, 2012, , 156-157.	0.2	0
202	Multiple System Atrophy. Current Clinical Neurology, 2012, , 30-31.	0.2	0
203	DYT1 Generalized Dystonia. Current Clinical Neurology, 2012, , 80-81.	0.2	0
204	Friedreich's Ataxia. Current Clinical Neurology, 2012, , 228-229.	0.2	0
205	Medical therapy for dystonia. , 2012, , 357-373.		0
206	Myoclonus and Startle Syndromes. , 2017, , 315-325.		0
207	Doctor Hope; Calming and Comforting Loneliness in Parkinson's Disease. Clinical Parkinsonism & Related Disorders, 2022, 6, 100131.	0.9	0
208	Tourette's syndrome: old syndrome, new insights and new treatment. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88, 1462-70.	0.1	0
209	Medical image. "Hot cross bun" sign. New Zealand Medical Journal, 2007, 120, U2563.	0.5	0
210	Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2009, 92, 142-54.	0.1	0
211	Title is missing!. , 2020, 15, e0243051.		0
212	Title is missing!. , 2020, 15, e0243051.		0
213	Title is missing!. , 2020, 15, e0243051.		0
214	Title is missing!. , 2020, 15, e0243051.		0
215	Title is missing!. , 2020, 15, e0243051.		0
216	Title is missing!. , 2020, 15, e0243051.		0